Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma – PubMed
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although cSCC contributes to substantial morbidity and mortality in high-risk individuals, deployment of otherwise effective chemoprevention of cSCC is limited by toxicities. Our systematic computational drug repurposing …